Market
What will be the confirmed reduction in dementia risk by Ozempic by end of 2025?
2
Resolution / Starting Odds
70% or more reduction • 25%
50-69% reduction • 25%
25-49% reduction • 25%
Less than 25% reduction • 25%
Final study results published by credible scientific journals or announced by the research institutions involved
Story
Ozempic Shows Promise in Reducing Advanced Alzheimer's Risk, Potential 70% Reduction in Dementia by 2025
Dec 26, 2024, 08:53 AM
Recent studies are exploring the potential of Ozempic, a weight-loss medication, to aid in the fight against advanced Alzheimer's disease. Scientists are investigating its anti-inflammatory properties, which may contribute to a significant reduction in the risk of developing dementia. Early findings indicate that patients receiving the medication could see up to a 70% reduced risk of dementia. However, further research is needed, with more comprehensive results expected in 2025.
View original story
Similar markets
Study retracted • 25%
Inconclusive results • 25%
Confirms significant risk • 25%
No significant risk found • 25%
Other regulatory actions • 25%
Safety label update • 25%
Product recall • 25%
No action taken • 25%
Approve distribution city-wide • 25%
No distribution approved • 25%
No decision made • 25%
Approve limited distribution • 25%
Dementia • 25%
Heart attack • 25%
Substance abuse • 25%
Schizophrenia • 25%
22% to 24% weight loss • 25%
20% to 22% weight loss • 25%
More than 24% weight loss • 25%
Less than 20% weight loss • 25%
Weight loss > 20.7% • 25%
Weight loss between 19% and 20.7% • 25%
Weight loss between 17.5% and 19% • 25%
Weight loss < 17.5% • 25%
0-10% • 25%
31% or more • 25%
21-30% • 25%
11-20% • 25%
By both • 25%
By health organizations • 25%
By Novo Nordisk • 25%
No campaigns • 25%
Heart Disease • 25%
Chronic Kidney Disease • 25%
Stroke • 25%
Other • 25%